Gossamer Bio
GOSS
93 hedge funds and large institutions have $165M invested in Gossamer Bio in 2024 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 31 increasing their positions, 29 reducing their positions, and 25 closing their positions.
7% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 29
3% more call options, than puts
Call options by funds: $591K | Put options by funds: $576K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6.86% less ownership
Funds ownership: 87.69% → 80.83% (-6.9%)
14% less funds holding
Funds holding: 108 → 93 (-15)
52% less capital inflows, than outflows
Capital inflows: $19.6M | Capital outflows: $40.9M
56% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$4.11M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.95M |
| 3 |
6CM
683 Capital Management
New York
|
+$1.87M |
| 4 |
NEA Management Company
Timonium,
Maryland
|
+$1.69M |
| 5 |
Monaco Asset Management
Monaco
|
+$1.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EcoR1 Capital
San Francisco,
California
|
-$10.9M |
| 2 |
Farallon Capital Management
San Francisco,
California
|
-$7.23M |
| 3 |
Madison Avenue Partners
New York
|
-$4.89M |
| 4 |
Morgan Stanley
New York
|
-$3.1M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.95M |
GOSS Hedge Fund Activity: Q2 2024 in Review
93 of the 6,941 institutional investors tracked by Wall St. Rank reported a position in Gossamer Bio (GOSS) for Q2 2024, worth a combined $165M — down 29% from $234M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of GOSS and 11 opened new positions — a net loss of 14 holders — while 29 trimmed existing stakes and 31 added.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $4.11M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $10.9M sold.
- 93 institutional investors held Gossamer Bio (GOSS) as of Q2 2024, down from 108 in Q1 2024.
- Funds reported $165M of Gossamer Bio stock for Q2 2024, down 29% quarter-over-quarter.
- 11 funds opened new Gossamer Bio positions in Q2 2024 and 25 closed out, a net change of -14 holders.
- The largest Gossamer Bio buyer in Q2 2024 was Alyeska Investment Group, an estimated $4.11M added.
- The largest Gossamer Bio seller in Q2 2024 was EcoR1 Capital, an estimated $10.9M sold.
Based on aggregated 13F filings for Q2 2024.